// App-Quantinova.ai

: MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Researchers

Presenter

  • Stefan Knop

Principal Investigators

  • Hartmut Goldschmidt

  • Marc S Raab

  • Monika Szarejko

  • Artur Jurczyszyn

  • Jan Drig

  • Sara Bringhen

  • Barbara Gamberi

  • Angelo Vacca

  • Jorge Castellano Acosta

  • Guy Lemaillet

  • Cedric Cortijo

  • Bansod Sudhir

  • Norbert Grzasko

Medical Centers

  • Wurzburg University Medical Center, Wurzburg, Germany

  • Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany

  • Dept. of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

  • University Clinical Centre, Department of Hematology and Transplantology, Gdansk, POL

  • University Hospital, Krakow, POL

  • Department of Surgery, University Hospital Essen, Essen, Germany

  • Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

  • Oncologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

  • University of Bari Aldo Moro, Bari, Italy

  • Molecular Partners AG, London, United Kingdom

  • Molecular Partners AG, Zurich-Schlieren, Switzerland

  • Exparimental Hematooncology Department, Medical University of Lublin, Lublin, Poland

Locations

  • Germany

  • Poland

  • Italy

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

  • MP0250

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Multinational

  • Dose Escalation

Phase

  • II

Study Id's

  • NCT03136653

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved